Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (OPTEX2/3)
This study is ongoing, but not recruiting participants.
Sponsor:
HepNet Study House, German Liverfoundation
Collaborator:
Hannover Clinical Trial Center GmbH
Information provided by (Responsible Party):
HepNet Study House, German Liverfoundation
ClinicalTrials.gov Identifier:
NCT00803309
First received: December 4, 2008
Last updated: December 6, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |